Ypsomed Holding AG (YPHDF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ypsomed Holding AG (YPHDF) with AI Score 50/100 (Hold). Ypsomed Holding AG specializes in developing and manufacturing injection and infusion systems, catering to pharmaceutical and biotechnology companies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Ypsomed Holding AG (YPHDF) Healthcare & Pipeline Overview
Ypsomed Holding AG, a Swiss-based company, develops and markets advanced injection and infusion systems, primarily serving the diabetes care and drug delivery markets. With a focus on innovation and strategic partnerships, Ypsomed offers solutions like pen injectors and insulin pumps, positioning itself as a key player in the global medical device landscape.
Investment Thesis
Ypsomed Holding AG presents a compelling investment case driven by its strong market position in the drug delivery and diabetes care sectors. The company's focus on innovative injection and infusion systems, coupled with its strategic partnerships with pharmaceutical and biotechnology companies, positions it for sustained growth. With a profit margin of 24.6% and an ROE of 27.2%, Ypsomed demonstrates strong financial performance. Key growth catalysts include the increasing demand for self-injection devices and the expansion of its diabetes care product line. However, investors should be aware of the company's debt-to-equity ratio of 1.24 and negative free cash flow. The company's beta of 0.88 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $5.54B reflects Ypsomed's significant presence in the medical device market.
- Profit Margin of 24.6% indicates strong profitability and efficient operations.
- Gross Margin of 39.3% demonstrates the company's ability to manage production costs effectively.
- Return on Equity (ROE) of 27.2% signifies efficient use of shareholder equity to generate profits.
- Beta of 0.88 suggests lower volatility compared to the overall market, potentially offering stability to investors.
Competitors & Peers
Strengths
- Innovative product portfolio
- Strong relationships with pharmaceutical companies
- Established brand in the diabetes care market
- Scalable manufacturing capabilities
Weaknesses
- High debt-to-equity ratio
- Negative free cash flow
- Dependence on key partnerships
- Limited geographic presence in some regions
Catalysts
- Upcoming: Potential FDA approval for a new drug delivery system developed in partnership with a major pharmaceutical company.
- Ongoing: Increasing adoption of Ypsomed's insulin pumps and blood glucose monitoring systems in the diabetes care market.
- Ongoing: Expansion into new geographic markets, particularly in Asia and Latin America.
- Ongoing: Strategic partnerships with pharmaceutical companies to develop customized drug delivery solutions.
Risks
- Potential: Intense competition from larger medical device companies with greater resources.
- Potential: Regulatory changes in the healthcare industry that could impact the company's operations.
- Potential: Economic downturns that could reduce healthcare spending and demand for Ypsomed's products.
- Ongoing: High debt-to-equity ratio, which could limit the company's financial flexibility.
- Ongoing: Dependence on key partnerships, which could be disrupted if these relationships are terminated.
Growth Opportunities
- Expansion in Wearable Injectors: The market for wearable injectors is rapidly expanding, driven by the increasing demand for convenient and patient-friendly drug delivery solutions. Ypsomed's expertise in developing wearable injectors positions it to capitalize on this trend. The global wearable injectors market is projected to reach billions of dollars in the coming years, offering a significant growth opportunity for Ypsomed. Timeline: Ongoing.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop customized drug delivery solutions is a key growth driver for Ypsomed. These partnerships enable the company to integrate its injection systems with new and existing drugs, creating a synergistic relationship. The pharmaceutical industry's increasing focus on patient-centric drug delivery methods further enhances this opportunity. Timeline: Ongoing.
- Growth in Diabetes Care Segment: The global diabetes market continues to expand, driven by the rising prevalence of diabetes and the increasing demand for advanced diabetes management solutions. Ypsomed's Diabetes Care segment, with its mylife brand, is well-positioned to benefit from this trend. The company's focus on innovative insulin pumps and blood glucose monitoring systems provides a competitive edge. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Latin America, represents a significant growth opportunity for Ypsomed. These regions are experiencing rapid economic growth and increasing healthcare spending, creating a favorable environment for medical device companies. Ypsomed's international distribution network and strategic partnerships facilitate its geographic expansion efforts. Timeline: Ongoing.
- Development of Smart Devices: Integrating digital technologies into its injection and infusion systems is a key growth driver for Ypsomed. The development of smart devices that can track medication adherence, provide personalized feedback, and connect with healthcare providers offers significant value to patients and healthcare professionals. The increasing adoption of digital health solutions further enhances this opportunity. Timeline: Ongoing.
Opportunities
- Expansion in wearable injectors market
- Growth in emerging markets
- Development of smart devices
- Increased demand for self-administered medications
Threats
- Intense competition from larger medical device companies
- Regulatory changes in the healthcare industry
- Economic downturns that could reduce healthcare spending
- Technological advancements that could render existing products obsolete
Competitive Advantages
- Proprietary Technology: Ypsomed's innovative injection and infusion systems are protected by patents and trade secrets, creating a barrier to entry for competitors.
- Strategic Partnerships: The company's strong relationships with pharmaceutical and biotechnology companies provide a competitive advantage.
- Established Brand: The mylife brand is well-recognized and trusted in the diabetes care market.
- Scalable Manufacturing: Ypsomed's manufacturing facilities are designed to handle large-scale production, enabling the company to meet growing demand.
About YPHDF
Founded in 1984 and headquartered in Burgdorf, Switzerland, Ypsomed Holding AG has evolved into a prominent player in the development and manufacturing of injection and infusion systems. The company operates through two primary segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment focuses on providing injection systems, including pen injectors, auto-injectors, patch injectors, and wearable injectors, marketed under the YDS brand. These systems are crucial for delivering various medications, particularly in the pharmaceutical and biotechnology sectors. The Ypsomed Diabetes Care segment is dedicated to the diabetes market, offering insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, and related accessories under the mylife brand. This segment aims to improve the lives of individuals with diabetes through innovative and user-friendly products. Ypsomed also provides precision turned parts and contract manufacturing services, further diversifying its revenue streams. The company distributes its products through a network of biotechnology and pharmaceutical partners, as well as through its own distribution channels and independent distributors, reaching markets in Switzerland, Europe, North America, and internationally. Ypsomed's commitment to innovation and strategic partnerships has enabled it to maintain a competitive edge in the medical device industry.
What They Do
- Develops pen injectors for pharmaceutical and biotechnology companies.
- Manufactures auto-injectors for self-administered medications.
- Produces patch injectors for continuous drug delivery.
- Creates wearable injectors for convenient and discreet drug administration.
- Offers insulin pumps and infusion sets for diabetes management.
- Provides blood glucose monitoring systems and accessories for diabetics.
- Manufactures precision turned parts for various industries.
- Offers contract manufacturing services to other companies.
Business Model
- Sells injection systems to pharmaceutical and biotechnology companies.
- Markets diabetes care products directly to consumers and through distributors.
- Provides contract manufacturing services to other companies.
- Generates revenue through the sale of accessories and consumables.
Industry Context
Ypsomed Holding AG operates within the medical device industry, specifically focusing on drug delivery systems and diabetes care. The market for injection and infusion systems is experiencing growth due to the increasing prevalence of chronic diseases and the rising demand for self-administered medications. The competitive landscape includes companies like Medtronic and Insulet, which offer similar products and services. Ypsomed differentiates itself through its focus on innovation, strategic partnerships, and a comprehensive product portfolio catering to both pharmaceutical companies and individual patients.
Key Customers
- Pharmaceutical companies that use Ypsomed's injection systems to deliver their drugs.
- Biotechnology companies that require specialized drug delivery solutions.
- Individuals with diabetes who use Ypsomed's insulin pumps and blood glucose monitoring systems.
- Healthcare providers who recommend and prescribe Ypsomed's products to their patients.
Financials
Chart & Info
Ypsomed Holding AG (YPHDF) stock price: Price data unavailable
Latest News
-
When Should You Buy Ypsomed Holding AG (VTX:YPSN)?
Yahoo! Finance: YPHDF News · Feb 14, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for YPHDF.
Price Targets
Wall Street price target analysis for YPHDF.
MoonshotScore
What does this score mean?
The MoonshotScore rates YPHDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Simon Michel
CEO
Simon Michel serves as the CEO of Ypsomed Holding AG, leading a workforce of 2600 employees. His career reflects a deep understanding of the medical device industry and a commitment to innovation. Prior to his role at Ypsomed, Michel held various leadership positions in the healthcare sector, focusing on strategic development and market expansion. His educational background includes advanced degrees in business administration and engineering, providing him with a strong foundation for managing a complex and technology-driven organization.
Track Record: Under Simon Michel's leadership, Ypsomed has experienced significant growth and expansion, particularly in the areas of drug delivery systems and diabetes care. Key achievements include the successful launch of new products, the establishment of strategic partnerships with pharmaceutical companies, and the expansion into new geographic markets. Michel's strategic decisions have positioned Ypsomed as a key player in the global medical device landscape.
YPHDF OTC Market Information
The OTC Other tier, where Ypsomed Holding AG (YPHDF) trades, represents the lowest of the three tiers of OTC markets. Companies in this tier often have limited or no financial disclosure and may not meet the minimum requirements for listing on higher tiers like OTCQX or OTCQB. This tier is generally considered to be the most speculative and carries the highest risk due to the lack of transparency and regulatory oversight compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: The low trading volume can lead to price volatility and difficulty in buying or selling shares.
- Regulatory Risks: OTC-traded companies are subject to less regulatory oversight than exchange-listed companies, increasing the risk of fraud or mismanagement.
- Information Asymmetry: The limited availability of information can create an uneven playing field for investors.
- Delisting Risk: There is a risk that the company could be delisted from the OTC market if it fails to meet certain requirements.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape and its position within the industry.
- Understand the risks associated with investing in OTC-traded companies.
- Consult with a financial advisor before making any investment decisions.
- Established Operations: Ypsomed Holding AG has been in operation since 1984, suggesting a degree of stability and experience.
- International Presence: The company operates in multiple countries, indicating a broader market reach.
- Partnerships: Collaborations with pharmaceutical and biotechnology companies lend credibility to its operations.
- Employee Count: The company employs approximately 2600 people, suggesting a substantial business operation.
What Investors Ask About Ypsomed Holding AG (YPHDF)
What does Ypsomed Holding AG do?
Ypsomed Holding AG develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies, as well as diabetes care products for individuals with diabetes. The company operates through two segments: Ypsomed Delivery Systems, which provides injection systems like pen injectors and auto-injectors, and Ypsomed Diabetes Care, which offers insulin pumps, blood glucose monitoring systems, and related accessories. Ypsomed serves both pharmaceutical partners and individual patients, focusing on innovative and user-friendly solutions.
What do analysts say about YPHDF stock?
Analyst coverage of YPHDF is limited due to its OTC listing. However, the company's strong market position in the drug delivery and diabetes care sectors, coupled with its innovative product portfolio, suggests potential for growth. Key valuation metrics include its market capitalization of $5.54B, profit margin of 24.6%, and ROE of 27.2%. Investors may want to evaluate the company's high debt-to-equity ratio and negative free cash flow when evaluating its financial health. Analyst consensus is Unknown.
What are the main risks for YPHDF?
The main risks for Ypsomed Holding AG include intense competition from larger medical device companies, regulatory changes in the healthcare industry, and economic downturns that could reduce healthcare spending. The company's high debt-to-equity ratio and negative free cash flow also pose financial risks. Additionally, Ypsomed's dependence on key partnerships could be disrupted if these relationships are terminated. Investors should carefully consider these risks before investing in YPHDF.
What are the key factors to evaluate for YPHDF?
Ypsomed Holding AG (YPHDF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Innovative product portfolio. Primary risk to monitor: Potential: Intense competition from larger medical device companies with greater resources.. This is not financial advice.
How frequently does YPHDF data refresh on this page?
YPHDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven YPHDF's recent stock price performance?
Recent price movement in Ypsomed Holding AG (YPHDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative product portfolio. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider YPHDF overvalued or undervalued right now?
Determining whether Ypsomed Holding AG (YPHDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying YPHDF?
Before investing in Ypsomed Holding AG (YPHDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available information and may not be comprehensive.